AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21960668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg single dose)
Number of subjects: 20
Study 19678944 — intervention group
Group type: EXPERIMENTAL
Intervention: TTT intervention (Train the trainer)
Number of subjects: 168
Study 19678944 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168
Study 17445634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (125 mg) every 8 hours (maximum of 21 doses)
Number of subjects: 22
Study 17445634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15064295 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage-based e-mail system
Number of subjects: 3007
Study 19759966 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy conservation training (1 to 2 hours of individual training followed by weekly telephone monitoring for 3 weeks)
Number of subjects: 12
Study 19759966 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (standard care from oncologist)
Number of subjects: 12
Study 10555027 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) 2000 mg/day
Number of subjects: 619
Study 10555027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study 8707971 — intervention group
Group type: EXPERIMENTAL
Intervention: Active prescale gel
Number of subjects: 10
Study 8707971 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 10
Study 8707971 — intervention group
Group type: EXPERIMENTAL
Intervention: Active prescale gel (extended exposure)
Number of subjects: 10
Study 1762068 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg of morphine
Number of subjects: 5
Study 1762068 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of morphine
Number of subjects: 5
Study 1762068 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of morphine
Number of subjects: 5
Study 1762068 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of morphine
Number of subjects: 5
Study 1762068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 1762068 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest dose of morphine (not specified)
Number of subjects: 5
Study 1762068 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate doses of morphine (not specified)
Number of subjects: 5
Study 1762068 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest dose of morphine (30 mg)
Number of subjects: 5
Study 6347229 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily
Number of subjects: 20
Study 6347229 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol SA 200 mg once daily
Number of subjects: 20
Study 31389784 — intervention group
Group type: EXPERIMENTAL
Intervention: methyl‐5‐aminolevulinate 16% cream-Photodynamic therapy (PDT)
Number of subjects: 10
Study 31389784 — intervention group
Group type: EXPERIMENTAL
Intervention: imiquimod 5% cream
Number of subjects: 10
Study 29739371 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation (Rehab, n = 43)
Number of subjects: 193
Study 29739371 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive exercises (Physio, n = 43)
Number of subjects: 193
Study 29739371 — intervention group
Group type: COMPARATOR
Intervention: Self-care advice (Advice, n = 40)
Number of subjects: 193
Study 29739371 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 193
Study 27352310 — intervention group
Group type: EXPERIMENTAL
Intervention: Baicalein 200 mg once daily on days 1 and 10, twice daily on days 3-9
Number of subjects: 36
Study 27352310 — intervention group
Group type: EXPERIMENTAL
Intervention: Baicalein 400 mg once daily on days 1 and 10, twice daily on days 3-9
Number of subjects: 36
Study 27352310 — intervention group
Group type: EXPERIMENTAL
Intervention: Baicalein 800 mg once daily on days 1 and 10, twice daily on days 3-9
Number of subjects: 36
Study 27352310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24827888 — intervention group
Group type: EXPERIMENTAL
Intervention: Red grape cells (RGC)
Number of subjects: 0
Study 24827888 — intervention group
Group type: EXPERIMENTAL
Intervention: RGC-derived resveratrol (RES)
Number of subjects: 0
Study 22958313 — intervention group
Group type: EXPERIMENTAL
Intervention: Stern‐E‐Fix corset postoperatively for 6 weeks
Number of subjects: 750
Study 22958313 — intervention group
Group type: COMPARATOR
Intervention: Standard elastic thorax bandage
Number of subjects: 750
Study 20925995 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound
Number of subjects: 90
Study 20925995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound
Number of subjects: 90
Study 20925995 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) ultrasound
Number of subjects: 90
Study 18403402 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 425
Study 18403402 — intervention group
Group type: COMPARATOR
Intervention: Mock TENS (control)
Number of subjects: 425
Study 15814399 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 pneumoperitoneum
Number of subjects: 145
Study 15814399 — intervention group
Group type: COMPARATOR
Intervention: Room air pneumoperitoneum
Number of subjects: 145
Study 12457671 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (5 microg bolus doses via PCA after IV loading dose of 0.7 microg/kg)
Number of subjects: 68
Study 12457671 — intervention group
Group type: COMPARATOR
Intervention: Control group (balanced salt solution without analgesic via PCA)
Number of subjects: 68
Study 10542999 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-inhibitor administration
Number of subjects: 0
Study 10542999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8949757 — intervention group
Group type: EXPERIMENTAL
Intervention: twice‐daily neutron therapy for advanced head and neck cancer
Number of subjects: 721
Study 8949757 — intervention group
Group type: EXPERIMENTAL
Intervention: neutron therapy for advanced salivary gland tumours
Number of subjects: 721
Study 8949757 — intervention group
Group type: EXPERIMENTAL
Intervention: neutron therapy for locally advanced breast cancer
Number of subjects: 721
Study 8949757 — intervention group
Group type: EXPERIMENTAL
Intervention: neutron therapy for macroscopic residual soft tissue sarcomas
Number of subjects: 721
Study 8949757 — intervention group
Group type: EXPERIMENTAL
Intervention: neutron therapy for macroscopic residual uterine sarcoma
Number of subjects: 721
Study 8949757 — intervention group
Group type: EXPERIMENTAL
Intervention: neutron therapy for advanced squamous carcinoma of the maxillary antrum
Number of subjects: 721
Study 8949757 — intervention group
Group type: EXPERIMENTAL
Intervention: neutron therapy for advanced osteosarcomas and chondrosarcomas
Number of subjects: 721
Study 1681558 — intervention group
Group type: EXPERIMENTAL
Intervention: Loprazolam 2 mg
Number of subjects: 12
Study 1681558 — intervention group
Group type: EXPERIMENTAL
Intervention: Loprazolam 1 mg
Number of subjects: 12
Study 1681558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31234842 — intervention group
Group type: COMPARATOR
Intervention: School-located influenza vaccination (SLIV) in elementary schools
Number of subjects: 80
Study 31234842 — intervention group
Group type: COMPARATOR
Intervention: School-located influenza vaccination (SLIV) in secondary schools
Number of subjects: 80
Study 31234842 — intervention group
Group type: EXPERIMENTAL
Intervention: School-located influenza vaccination (SLIV) in elementary schools with spillover impact
Number of subjects: 80
Study 31234842 — intervention group
Group type: EXPERIMENTAL
Intervention: School-located influenza vaccination (SLIV) in secondary schools with spillover impact
Number of subjects: 80
Study 28261955 — intervention group
Group type: EXPERIMENTAL
Intervention: Beloranib 1.8 mg subcutaneously twice weekly for 4 weeks
Number of subjects: 14
Study 28261955 — intervention group
Group type: EXPERIMENTAL
Intervention: Beloranib 1.8 mg (after 4-week open-label extension)
Number of subjects: 14
Study 28261955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 28261955 — intervention group
Group type: EXPERIMENTAL
Intervention: Beloranib treatment
Number of subjects: 14
Study 26344014 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol for 28 days
Number of subjects: 60
Study 26344014 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 60
Study 23150685 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure at 19 C
Number of subjects: 0
Study 23150685 — intervention group
Group type: COMPARATOR
Intervention: Exposure at 24 C
Number of subjects: 0
Study 23150685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-induced increase in FGF21
Number of subjects: 0
Study 23150685 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in area under the curve plasma FGF21 between 19 and 24 C
Number of subjects: 0
Study 20932798 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% maltodextrin solution [Mal]
Number of subjects: 14
Study 20932798 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.1% glucose solution [Glu]
Number of subjects: 14
Study 20932798 — intervention group
Group type: EXPERIMENTAL
Intervention: water [Wa]
Number of subjects: 14
Study 20932798 — intervention group
Group type: COMPARATOR
Intervention: control trial with no rinse [Con]
Number of subjects: 14
Study 19344032 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching wide‐diameter prosthetic components (group A)
Number of subjects: 144
Study 19344032 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform‐switched prosthetic components (group B)
Number of subjects: 144
Study 16464289 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with OCD
Number of subjects: 0
Study 16464289 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents and adults with OCD
Number of subjects: 0
Study 16464289 — intervention group
Group type: EXPERIMENTAL
Intervention: All age groups (children, adolescents, adults)
Number of subjects: 0
Study 15023579 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased orbitofrontal cortex to amygdala ratio (OAR) in men with schizophrenia
Number of subjects: 111
Study 15023579 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased orbitofrontal cortex to amygdala ratio (OAR) in women with schizophrenia
Number of subjects: 111
Study 15023579 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased OAR in men
Number of subjects: 111
Study 15023579 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased OAR in women
Number of subjects: 111
Study 15023579 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased amygdala volume in men
Number of subjects: 111
Study 15023579 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher volumes of both amygdala and orbitofrontal regions in women
Number of subjects: 111
Study 11316092 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% and Timolol 0.5%
Number of subjects: 20
Study 11316092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9399007 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary headache sufferers (MO, MA, TH)
Number of subjects: 430
Study 7653736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 328
Study 7653736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 328
Study 7653736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 2.5 mg
Number of subjects: 328
Study 7653736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 3300580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (CM)
Number of subjects: 20
Study 3300580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (CZ)
Number of subjects: 20
Study 3300580 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (V)
Number of subjects: 20
Study 31441852 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (continuous infusion with 0.01 mg/kg/h and a bolus dose with 0.03 mg/kg)
Number of subjects: 90
Study 31441852 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (a bolus dose with 0.03 mg/kg)
Number of subjects: 90
Study 31441852 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (PCA administered as a time‐scheduled decremental continuous infusion based on lean body mass)
Number of subjects: 90
Study 31441852 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 90
Study 29112754 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal of 'never smoke again'
Number of subjects: 1043
Study 29112754 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal of 'taking it a cigarette at a time'
Number of subjects: 1043
Study 29112754 — intervention group
Group type: COMPARATOR
Intervention: Goal of 'seeing how it will go'
Number of subjects: 1043
Study 25130962 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselors who received a summary of the questionnaire results prior to the telephone session
Number of subjects: 118
Study 25130962 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone session with feedback on psychosocial problems
Number of subjects: 118
Study 25130962 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine extension of the CGCT procedure
Number of subjects: 118
Study 23532477 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 328
Study 21912321 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty (BKP)
Number of subjects: 63
Study 21912321 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (control)
Number of subjects: 63
Study 19781402 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 270
Study 19781402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 270
Study 19781402 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 270
Study 16962938 — intervention group
Group type: EXPERIMENTAL
Intervention: High phenolic content virgin olive oil (25 ml/day for 3 weeks)
Number of subjects: 28
Study 12618946 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropuncture laparoscopic cholecystectomy (MPLC)
Number of subjects: 40
Study 12618946 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 40
Study 11193166 — intervention group
Group type: EXPERIMENTAL
Intervention: Talsaclidine (selective muscarinic M1 agonist), administered for 4 weeks
Number of subjects: 24
Study 11193166 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group), administered for 4 weeks
Number of subjects: 24
Study 9076645 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen implant
Number of subjects: 40
Study 9076645 — intervention group
Group type: COMPARATOR
Intervention: Placebo implant
Number of subjects: 40
Study 8376594 — intervention group
Group type: EXPERIMENTAL
Intervention: E2348/69 EPEC strain (wild-type)
Number of subjects: 11
Study 8376594 — intervention group
Group type: COMPARATOR
Intervention: eaeA deletion mutant
Number of subjects: 11
Study 3790956 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g IV/8 h for 2 days)
Number of subjects: 226
Study 3790956 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (1 g IV on induction and 12 h postoperatively)
Number of subjects: 226
Study 30012018 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-washing education or promotional materials
Number of subjects: 222599
Study 30012018 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hand-washing education or promotional materials)
Number of subjects: 222599
Study 27734319 — intervention group
Group type: EXPERIMENTAL
Intervention: MMI plus selenium
Number of subjects: 30
Study 27734319 — intervention group
Group type: COMPARATOR
Intervention: MMI
Number of subjects: 30
Study 25292280 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain cigarette packs
Number of subjects: 144
Study 25292280 — intervention group
Group type: COMPARATOR
Intervention: Branded cigarette packs
Number of subjects: 144
Study 25292280 — intervention group
Group type: COMPARATOR
Intervention: No-stimulus condition
Number of subjects: 144
Study 25292280 — intervention group
Group type: COMPARATOR
Intervention: Plain cigarette packs vs Branded cigarette packs
Number of subjects: 144
Study 25292280 — intervention group
Group type: COMPARATOR
Intervention: Plain cigarette packs vs No-stimulus condition
Number of subjects: 144
Study 23011911 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT) with concurrent 5-fluorouracil/mitomycin C
Number of subjects: 292
Study 21736599 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival debridement by glycine powder/air polishing
Number of subjects: 20
Study 21736599 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic instrumentation
Number of subjects: 20
Study 20110036 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC‐AQ 300 microg
Number of subjects: 30
Study 20110036 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC‐HFA 300 microg
Number of subjects: 30
Study 20110036 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC HFA‐MDI 320 microg
Number of subjects: 30
Study 20110036 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 30
Study 16422140 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-matched intervention
Number of subjects: 208
Study 16422140 — intervention group
Group type: COMPARATOR
Intervention: Social-cognitive intervention
Number of subjects: 208
Study 16422140 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 208
Study 15521216 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated autohemotherapy (O3‐AHT) with ozone concentration of 50 microg/ml
Number of subjects: 12
Study 15521216 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control (autohemotherapy without ozone exposure)
Number of subjects: 12
Study 15521216 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurement
Number of subjects: 12
Study 11463111 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 219
Study 11463111 — intervention group
Group type: COMPARATOR
Intervention: mefloquine-artesunate
Number of subjects: 219
Study 9726386 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole/day
Number of subjects: 114
Study 9726386 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine/day
Number of subjects: 114
Study 9726386 — intervention group
Group type: EXPERIMENTAL
Intervention: Termination of therapy
Number of subjects: 114
Study 8027291 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml insemination
Number of subjects: 177
Study 8027291 — intervention group
Group type: COMPARATOR
Intervention: 0.25 ml insemination
Number of subjects: 177
Study 2572101 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with MC 903 (new synthetic vitamin D3 analogue)
Number of subjects: 5
Study 2572101 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 5
Study 1178407 — intervention group
Group type: EXPERIMENTAL
Intervention: Red illumination
Number of subjects: 40
Study 1178407 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow illumination
Number of subjects: 40
Study 1178407 — intervention group
Group type: COMPARATOR
Intervention: Blue illumination
Number of subjects: 40
Study 1178407 — intervention group
Group type: COMPARATOR
Intervention: Green illumination
Number of subjects: 40
Study 29486765 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiangbin prescription (XBP)
Number of subjects: 0
Study 29486765 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26272266 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tannin green tea mouthwash
Number of subjects: 40
Study 26272266 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash
Number of subjects: 40
Study 26263802 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary repair of GHH via laparoscopic surgery (95% completed, mesh in 6%, Collis gastroplasty in 7%)
Number of subjects: 455
Study 26263802 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary repair of GHH
Number of subjects: 455
Study 23893178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (complete substitution)
Number of subjects: 194
Study 23893178 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (partial substitution)
Number of subjects: 194
Study 23893178 — intervention group
Group type: COMPARATOR
Intervention: Control (TESS score)
Number of subjects: 194
Study 21918156 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax AWS video laryngoscope
Number of subjects: 105
Study 21918156 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (using a #4 blade)
Number of subjects: 105
Study 18770102 — intervention group
Group type: EXPERIMENTAL
Intervention: APPN-PCP collaborative model including pharmacological and psychosocial interventions
Number of subjects: 41
Study 17154779 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level motion perception (top-down processes)
Number of subjects: 0
Study 17154779 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical motion stimulus (when direction was not identified)
Number of subjects: 0
Study 17154779 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive, preattentive mechanism
Number of subjects: 0
Study 17154779 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down process (perceptual awareness of motion direction)
Number of subjects: 0
Study 12669883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 48
Study 12669883 — intervention group
Group type: EXPERIMENTAL
Intervention: AH 26
Number of subjects: 48
Study 12669883 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulp Canal Sealer
Number of subjects: 48
Study 12669883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac-Endo
Number of subjects: 48
Study 11129742 — intervention group
Group type: EXPERIMENTAL
Intervention: T'ai Chi training (two 1-hour classes per week for 12 weeks)
Number of subjects: 33
Study 11129742 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 33
Study 9183321 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat starch-containing product (4 to 6 portions daily for up to 1 year)
Number of subjects: 17